Immunotherapy for Head and Neck Cancer — Who It Is Actually For

Most people with head and neck cancer in India are not candidates for immunotherapy. It is used mainly when the cancer has returned after treatment, or has spread, and further surgery or radiation is not possible. Newly diagnosed, potentially curable disease is still treated with surgery, radiation and chemotherapy.

Eligibility is confirmed on tissue and on examination, never from a scan report alone. If you were told “you can take immunotherapy” without a biopsy-confirmed diagnosis and a PD-L1 result, ask what that advice was based on.

Immunotherapy is used in head and neck cancer mainly in the recurrent or metastatic setting — squamous cell cancer of the mouth, tongue, throat, voice box or sinuses that has come back after treatment, or has spread to other organs. It may be given alone or with chemotherapy, guided by PD-L1 testing.

Guidance changes. The positions above reflect NCCN and ESMO head and neck guidance current as of August 2026, and are reviewed at our tumour board rather than applied from a printout.

A minority of patients respond. Response rates for checkpoint-inhibitor immunotherapy in recurrent or metastatic head and neck cancer, as summarised in NCCN and ESMO guidance current in August 2026, sit broadly in the 15–20% range, and are higher where PD-L1 expression is strong. Most patients do not respond, and the plan is changed if scans show progression.

• A response is not the same as a permanent result. It means the cancer shrinks or stops growing on scans. In some of the patients who respond, that control lasts a long time. In others it does not.
• PD-L1 shifts the odds, it does not decide the outcome. Stronger expression is associated with a higher chance of response. Some patients with strong expression still do not respond, and some with weak expression do.
• Response takes time to judge. The first assessment scan is usually done after several cycles, not after the first infusion. Feeling no different in week two says very little either way.
• Progression means a change of plan, not a failure on your part. If the scan shows the cancer is growing, immunotherapy is stopped and other options — chemotherapy, radiation, or supportive care — are discussed openly.
• Nobody can tell you in advance which group you are in. Any doctor who promises you will respond is not describing this treatment accurately.

We deliberately do not attach survival numbers to this decision on a web page. Those figures depend on your stage, site, fitness and prior treatment, and they belong in a 45-minute consultation with your own reports in front of you — not in a paragraph written for everybody.

Checkpoint-inhibitor immunotherapy does not attack the tumour directly. It blocks a signal that head and neck cancer cells use to switch off the immune cells sent to kill them. Releasing that brake allows the body’s own T-cells to recognise and attack the cancer, which is why the effect is slower to appear than chemotherapy’s.

Head and neck squamous cancers are relevant candidates for this approach for two reasons. Tumours driven by years of tobacco and areca-nut exposure carry a high load of genetic damage, which can make them more visible to the immune system. And many of these tumours express PD-L1, the protein that carries the “stand down” signal — which is exactly what the treatment is designed to interrupt.

Because the mechanism is immune, so are the side effects. Inflammation can appear in the skin, bowel, thyroid, liver, lungs, heart or adrenal glands. Reported early, most are manageable. That is the trade-off this treatment asks you to accept, and it should be explained to you before you consent, not afterwards.

Eligibility is worked out in a fixed sequence: confirm the diagnosis on tissue, test that tissue for PD-L1, score your general fitness, review your autoimmune and steroid history, then take the whole picture to a tumour board. No single test decides it, and no step is skipped to save time.

1. 1

   Confirm the diagnosis on tissue

   Biopsy slides are re-read by a pathologist. Squamous cell carcinoma of the mouth, tongue, throat or voice box is confirmed, and the site and extent are documented. Immunotherapy is never planned from a scan report alone.

2. 2

   PD-L1 testing on the tumour

   The same tissue is tested for PD-L1 expression, reported as a combined score. This does not give a yes-or-no answer, but it strongly shapes whether immunotherapy is used alone or alongside chemotherapy.

3. 3

   Score your general fitness

   Your oncologist records how much of the day you are up and active. Someone independent and mobile is in a very different position from someone confined to bed, and this weighs heavily on whether the treatment is likely to help or harm.

4. 4

   Review autoimmune history, steroids and other conditions

   Rheumatoid arthritis, thyroid disease, psoriasis, inflammatory bowel disease, past transplant, ongoing high-dose steroids, and uncontrolled infection including tuberculosis are all raised here. Some of these rule immunotherapy out. Others simply mean closer monitoring.

5. 5

   Tumour board review, then a written plan and a cost estimate

   Medical, surgical and radiation oncologists review the case together before anything is offered — not one doctor’s opinion. You then receive a written plan and a clear estimate, so the money conversation happens before the first cycle. Our cost of immunotherapy for head and neck cancer page sets out what drives that figure. All costs are indicative, as of August 2026.

Immunotherapy at CION is given as day care. You come in, the infusion runs over roughly 30 to 60 minutes, you are observed afterwards, and you go home the same day. Cycles repeat every two, three or six weeks. Blood tests are done before each cycle, and scans are used to judge whether it is working.

• Day-care infusion, no admission — a routine cycle does not need an overnight stay. Bring someone with you for the first cycle.
• Bloods before every cycle — thyroid, liver, kidney function and blood counts are checked each time, because immune side effects often show up on a blood test before you feel them.
• Response-assessment scans — PET-CT for response assessment is coordinated at partner imaging centres, not performed at CION. We arrange it, read it with you, and use it to decide whether to continue.
• Eating and swallowing support — head and neck cancer and its treatment make eating hard. A dietitian is part of the plan from the start, not called in after weight has already been lost.
• Report new symptoms the same day — new diarrhoea, a rash, breathlessness, chest pain, severe tiredness or a fast heartbeat are reported immediately, not saved for the next visit. Call 1800 202 8726 if something changes between cycles.
• Tell every other doctor you are on immunotherapy — including your dentist and any emergency doctor. Immune side effects are easily mistaken for ordinary infections.

Immunotherapy is administered as day care at CION centres. Response-assessment PET-CT is coordinated at partner imaging centres. CION does not provide CAR-T or other cell therapies.

If immunotherapy has been raised for your head and neck cancer, these companion pages cover the questions that usually come next — recurrence, cost, and how the same treatment is used in a cancer where it is far better established.

• Immunotherapy for Recurrent Oral Cancer — the single situation most head and neck patients in Telangana and AP are actually asking about, covered in detail.
• Cost of Immunotherapy for Head and Neck Cancer — what drives the figure, what scheme cover may apply, and why an estimate is given in writing before you start.
• Immunotherapy for Kidney Cancer: The New Standard — useful contrast: a cancer where immunotherapy has moved to the front of the pathway, which head and neck cancer has not.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is planned, delivered and monitored across our centres, and who decides.

One Conversation Can Settle the Question

Whether immunotherapy applies to you takes a tissue diagnosis, a PD-L1 result and an honest discussion — not a search result. Bring your reports and we will go through them with you.